Skip to content
SimSonGrowth Intelligence
All opportunitiesemerging molecule

Rusfertide

SimSon publishes no observed catalogue coverage for Rusfertide while an FDA novel drug approval dated 28 August 2026 is already in force — a near-term BUILD opportunity.Source

GAP
A commercially relevant molecule or product appears absent from SimSon while demand or catalyst evidence exists.
Here: SimSon coverage is no-listing-observed across every applicable probe, and a dated catalyst exists.
TIMING
A dated catalyst is forcing analytical work now — a novel approval, an NDSRI limit, a loss of exclusivity or a generic filing wave.
Here: A dated catalyst scores 87.9/100 and SimSon holds no observed coverage yet.
Recommended action
build

Make something SimSon does not currently list.

53.7/ 100 opportunity score
Medium confidenceMedium because market activity and competitor scarcity could not be scored from public evidence.
Recommended move

Scope a new rusfertide product family — no listing was observed at SimSon or at any checked supplier.

First step: Scientific feasibility review of the absent compounds, then confirm the absence at supplier level.

Review the absence evidence
Urgency
Act now
The catalyst is already in force — it dates from 2026-08-28, 1 month ago.
Owner
Not set
Owner is not set: the system has no access to SimSon's org chart and will not guess one.
Value — not public
Cannot be established
Revenue and margin are not public. This ranks the strength of the public signal, not the size of the prize — see what internal data would settle it.

Why now

  1. novel approvalSource

    rusfertide

    base 90 × 0.9767 recency = 87.9 / 100

Why SimSon

Observed from SimSon public catalogue · 13 SEPT 2026
0catalogue products observed for this molecule

This is an observed absence, not a failed search: every applicable probe completed against an identity-grade query before the verdict was recorded.

No listing was observed on SimSon's own catalogue for rusfertide after every applicable probe completed against an identity-grade query. This is an observed absence, not a failed search.Source

Organisations publicly associated with this molecule

No public filing record names an organisation for rusfertide in the current evidence set, so no buyer-candidate is asserted.

How this decision was reached

build
Rule fired
R1_GAP_TIMING

SimSon has no observed listing for this molecule, every applicable probe completed, and a dated catalyst is already in force.

No listing was observed at SimSon across every applicable probe, and the catalyst scores 87.9/100.

This is a system recommendation, not system evidence. It was selected by a fixed rule evaluated top to bottom over the values above — no model, no judgement. Change the inputs and the rule changes with them.

BUILD — rule R1_GAP_TIMING. No listing was observed at SimSon across every applicable probe, and the catalyst scores 87.9/100.

Opportunity score

Weighted over 55 of 100 available points · audit-01-phase2-v1
Market activity
Not scored
Regulatory catalyst
87.9
Competitor scarcity
Not scored
Capability adjacency
0.0
Evidence quality
75.8
Why competitor scarcity is not scored

Identity-grade competitor coverage was insufficient across the three suppliers this dimension requires. The 20 weight points it would have carried were removed from the denominator rather than scored as zero, so the remaining dimensions keep their relative influence.

A false competitive gap is materially worse than a missing scarcity score, so the dimension stays unscored until the evidence standard is met.

Market activity components
Distinct ANDA sponsors
Not available
Marketed products
Not available
Distinct trial sponsors
Not checked

ClinicalTrials.gov disallows our agent on /api/ in its robots.txt. The trial component was omitted from the weighted average rather than scored zero, and no substitute source was used.

Evidence ledger

2 items · 2 primary
  1. Retrieval datePrimaryLive retrieval
    SimSon Pharma LimitedSimSon public catalogueobserved

    SimSon catalogue coverage — rusfertide

    0 products observed on https://www.simsonpharma.com/products/rusfertide

    https://www.simsonpharma.com/products/rusfertide

    Retrieved 13 SEPT 2026

  2. Publisher datePrimaryLive retrieval
    U.S. Food and Drug AdministrationFDA novel drug approvals 2026observed

    rusfertide

    rusfertide; approved 2026-08-28; To treat erythrocytosis in adults with polycythemia vera

    https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

    Retrieved 13 SEPT 2026

What internal SimSon data would change this decision?

Everything above was built from information anyone can retrieve. The scoring is deterministic and the evidence is cited — but each of the following would sharpen this recommendation materially, and none of it is public.

Realised selling price and margin per catalogue item

Every opportunity here is ranked by signal strength, never by profit. A high-scoring molecule may be one SimSon sells at its thinnest margin.

Would be resolved by: SimSon price book and cost model

Synthesis feasibility and past success rate

Capability adjacency measures what SimSon has published, not what it can make. A BUILD recommendation is a question for the bench, not an instruction.

Would be resolved by: SimSon project history and R&D records

Actual competitor pricing, stock and terms

Public catalogues show listings, never terms. Even where a competitor listing is observed, it says nothing about price or availability.

Would be resolved by: Not public — sales intelligence or direct enquiry

Limitations recorded for this opportunity

competitor scarcity is NOT SCORED (0 of the 3 required suppliers hold an identity-grade verdict); the ClinicalTrials.gov trial-sponsor component is omitted from market activity because that publisher's robots.txt disallows our agent on /api/ — omitted, not scored zero.Source

Computed 14 SEPT 2026Weights audit-01-phase2-v1Run phase2-current-evidence-v1